Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2022 Nov 19;12:19927. doi: 10.1038/s41598-022-24467-0

A meta-analysis of effects of vitamin E supplementation alone and in combination with omega-3 or magnesium on polycystic ovary syndrome

Hajar Heidari 1, Zahra Hajhashemy 1,2, Parvane Saneei 1,✉
PMCID: PMC9675810  PMID: 36402830

Abstract

Vitamin E supplementation might have favorable effects on risk factors of polycystic ovary syndrome (PCOS). This systematic review and meta-analysis aimed to summarize the effects of vitamin E supplementation or vitamin E in combination with omega-3 or magnesium on PCOS. PubMed, Scopus, ISI Web of Science, Cochrane, Embase electronic databases, and Google scholar were searched for all available articles up to September 2022. Randomized controlled trials (RCTs) that examined the effect of vitamin E supplementation or vitamin E in combination with omega-3 or magnesium on lipid and glycemic profiles, anthropometric measurements, biomarkers of inflammation and oxidative stress, hormonal profile, and hirsutism score in patients with PCOS were included. Ten RCTs (with 504 participants) fulfilled the eligible criteria. Vitamin E supplementation or vitamin E in combination with omega-3 or magnesium in comparison to placebo could significantly reduce serum levels of TG (weighted mean difference: − 18.27 mg/dL, 95% CI − 34.68 to − 1.87), VLDL (− 5.88 mg/dL, 95% CI − 8.08 to − 3.68), LDL-c (− 12.84 mg/dL, 95% CI − 22.15 to − 3.52), TC (− 16.30 mg/dL, 95% CI − 29.74 to − 2.86), TC/HDL-c ratio (− 0.52, 95% CI − 0.87 to − 0.18), hs-CRP (− 0.60 ng/mL, 95% CI − 0.77 to − 0.44), hirsutism score (− 0.33, 95% CI − 0.65 to − 0.02) and significantly increase nitric oxide levels (2.79 µmol/L, 95% CI 0.79–4.79). No significant effect was found on HDL-c, glycemic indices, hormonal profile, anthropometric measurements, and other biomarkers of inflammation or oxidative stress. This meta-analysis highlights the potential anti-hyperlipidemic, anti-oxidant, and anti-inflammatory properties of vitamin E supplementation alone or in combination with omega-3 or magnesium on PCOS patients.

Subject terms: Obesity, Polycystic ovary syndrome, Nutrition

Introduction

Polycystic ovary syndrome (PCOS) is one of the most common and complex endocrine disturbances estimated to affect 6 to 25% of women in reproductive age1,2. PCOS is characterized by menstrual dysfunction, hyperandrogenism, ovulatory dysfunction, and subfertility3. Low-grade inflammation, including increased C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) plays a role in pathophysiology of PCOS4. Hyperinsulinemia and insulin resistance seem to be predominant features of PCOS, along with dysfunction of the hypothalamic-pituitary axis, which result in hormonal alterations, including increased serum luteinizing hormone (LH)/ follicle-stimulating hormone (FSH) ratio and circulating androgens. Dyslipidemia is also present in 70% of PCOS patients5,6. Thus, this syndrome can result in obesity and metabolic disorders like dyslipidemia, insulin resistance and increased hormonal and inflammatory disorders, and oxidative stress. Long-term consequences of PCOS are type 2 diabetes mellitus (T2DM), cardiovascular diseases (CVD), hypertension, cancer, and psychological problems7–9. Therefore, the adverse effects of PCOS could threaten the quality of life in women10.

The etiology of PCOS is unknown, but genetics along with environmental and lifestyle factors have been significantly implied in the development of the syndrome11,12. Lifestyle changes and nutritional interventions along with weight loss are successful treatments for patients with PCOS1. Dietary factors like anti-inflammatory foods may have a significant role in improving metabolic disorders of the syndrome10. Recently, there was an increasing attention to the health benefits of vitamin E. Vitamin E could possess anti-inflammatory, anti-oxidative, anti-hyperglycemic, anti-hypertensive, anti-hypercholesterolemic, and anti-obesity properties13.

Several clinical trials have examined the effect of vitamin E supplementation alone or in combination with omega-3 or magnesium on improving metabolic and hormonal profile, inflammatory markers, oxidative stress, hirsutism, and anthropometric parameters in PCOS patients, but controversial results have been reported2,14–23. Some trials showed that vitamin E supplementation alone or along with omega-3 could significantly improve total and free testosterone in PCOS patients15,16. In contrast, others reported that vitamin E and magnesium co-supplementation did not affect serum total testosterone levels14. Several studies indicated that vitamin E and magnesium or omega-3 co-supplementation might improve most indicators of lipid profiles in PCOS patients15,17. However, Izadi et al. suggested that vitamin E supplementation could only lead to a significant decrease in serum TG levels18. In addition, Chen et al. showed that short-term supplementation with vitamin E could improve oxidative stress markers such as malondialdehyde (MDA)19; while, other trials suggested that vitamin E supplementation along with magnesium did not affect MDA levels in PCOS patients14. To our knowledge, no previous review has systematically summarized the effects of vitamin E supplementation alone or along with omega-3 or magnesium on improvement of the metabolic and hormonal profile, inflammatory markers, oxidative stress, hirsutism, and anthropometric parameters in PCOS. So, we conducted a systematic review and meta-analysis on randomized clinical trials that evaluated the effects of vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation on PCOS patients.

Materials and methods

Search strategy

A comprehensive literature search was conducted of the MEDLINE (PubMed), Scopus, ISI Web of Science, Cochrane, and Embase electronic databases, as well as Google scholar, up to September 2022, with no limitation in language, time of publication or study location. The following combination of search terms was used: (“vitamin E” OR tocopherol OR tocotrienol OR “VIT E” OR “alpha-Tocopherol” OR “beta-Tocopherol” OR “gamma-Tocopherol” OR magnesium OR omega-3 OR “n-3 fatty acid” OR W-3 OR EPA OR DHA OR ALA OR “fish oil” OR “alpha-Linolenic Acid” OR “Docosahexaenoic Acids” OR “Eicosapentaenoic Acid”) AND (PCOS OR “polycystic ovarian syndrome” OR “Polycystic Ovary Syndrome”). Moreover, manual searches of the bibliographies of the relevant investigations were performed to avoid missing any publication. Duplicate citations were removed. The article selection was independently carried out by 2 investigators (H.H. and Z.H.), and any disagreement was resolved by consultation with the principal investigator (P.S.). The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline (PRISMA) were followed in the present report. The study protocol was registered at PROSPERO (no. CRD42021256820).

Inclusion and exclusion criteria

Published articles were included in the systematic review and meta-analysis if they met the following criteria: (1) be a randomized controlled trial (RCT); (2) conducted on women with PCOS; (3) supplemented intervention group with vitamin E or vitamin E in combination with omega-3 or magnesium, and control group with placebo; and (4) reported means and standard deviations (SDs) or standard errors (SEs) of lipid profile (TG, very low-density lipoprotein-cholesterol (VLDL), LDL-c, HDL-c, TC and TC/HDL-c ratio), glycemic indices (fasting blood sugar (FBS), insulin, homeostasis model assessment-estimated insulin resistance (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI)), hormonal parameters (total testosterone, serum luteinizing hormone (LH), follicle stimulating hormone (FSH), sex hormone-binding globulin (SHB) and free androgen index (FAI)), biomarkers of inflammation and oxidative stress (total antioxidant capacity (TAC), glutathione (GSH), MDA, high sensitive C-reactive protein (hs-CRP) and nitric oxide (NO)), anthropometric measurements (weight, body mass index (BMI), waist circumference and metabolic equivalents (METs)), and/or hirsutism score (ferriman–Gallwey (mf-G)), before and after supplementation. Studies were excluded if they did not provide integrated data or did not have an appropriate intervention. Details of more related studies that were excluded from the present review are described in Supplemental Table S1.

Data extraction

The following data were extracted from the eligible papers: first author’s name, publication year, study location, sample size of each intervention group, age range or mean age, number of participants in each group, study design, duration of intervention, dosage of vitamin E supplementation or vitamin E in combination with omega-3 or magnesium, type of intervention, and mean ± SD/SE of lipid and glycemic profiles, anthropometric measurements, biomarkers of inflammation and oxidative stress, hormonal profile and hirsutism score at baseline and the end of the intervention, matching of two intervention groups and final adjustments in the analysis. This process was independently performed by two investigators (H.H. and Z.H.). The principal researcher (P.S.) supervised data extraction. All reported SEs were converted to SDs using the appropriate formula. When the concentration of an indicator was reported in different units among included studies, we converted them to the most frequently used unit.

Quality assessment of studies

Revised Cochrane Collaboration's tools (RoB2.0) was used to assess the quality of each included RCT24. According to this tool, each trial was assessed based on the following domains: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other sources of bias. For each study, two authors have independently evaluated the risk of bias as low risk, high risk, and some concern for each domain. Finally, the overall quality of the study was categorized into: low risk, if the study was judged to be at low risk of bias for all domains; high risk, if the study was judged to be at high risk of bias in at least one domain; some concern, if the study was judged to be at some concern in at least one domain24.

Statistical analysis

To pool the effect of vitamin E supplementation or vitamin E in combination with omega-3 or magnesium supplementation on women with PCOS, the mean change and its standard deviation for intervention and control groups were extracted or calculated. Then, weighted mean differences (WMDs) with 95% confidence intervals (CIs) were computed through a random effects model. Between-study heterogeneity was tested by Cochran's Q test and quantified by I2 statistic. Subgroup analysis and meta-regression were performed to find the source of heterogeneity. Sensitivity analysis was used to explore the influence of a single study on the overall estimate. Publication bias was examined via visual inspection of funnel plots. A formal statistical assessment of funnel plot asymmetry was done using Begg’s and Egger’s tests. All statistical analyses were performed using STATA, version 11.2 (STATA Corp., College Station, TX). P values less than 0.05 were considered as statistically significant.

Results

Selection and identification of studies

Out of the initial 928 studies obtained by electronic and manual searches, 275 articles were excluded as duplicates. First, the title and abstract of the remaining 653 articles were screened, and 639 of them were excluded based on the inclusion criteria. Then, the full text of 14 articles was carefully assessed, and after excluding 4 irrelevant studies, 10 eligible RCTs were included in the present meta-analysis. It should be noted that Izadi et al. have conducted a trial on 43 women with PCOS and reported the results in two papers16,18; one of these papers showed the effect of vitamin E supplementation on lipid profile, and the other one reported the impact of vitamin E supplementation on glycemic and hormonal profiles. So, there was no overlapping in outcomes of interest, and we considered these reports as two trials. Finally, 10 RCTs were included in the present meta-analysis. A flow chart describing the systematic search and study selection process is illustrated in Fig. 1.

Figure 1.

Figure 1

Open in a new tab

Flow chart of the systematic search and study selection.

Systematic review

The main characteristics of 10 RCTs included in the systematic review and meta-analysis are described in Table 1. All eligible RCTs were carried out in Iran, published between 2017 and 2019, and had a sample size ranging from 40 to 68 participants. The mean age of participants in these trials ranged from 18 to 40 years. Duration of the intervention period varied from 8 to 12 weeks. In all RCTs, PCOS was defined based on the 2003 Rotterdam criteria. All RCTs had a parallel study design. The intervention group received vitamin E supplement in 3 trials2,16,18, vitamin E plus magnesium in 2 studies14,17, and vitamin E plus omega-3 in 5 studies15,20–23, while in all studies the control group received placebo. The dose of vitamin E for the intervention group ranged from 400 to 888 IU/day. Doses of omega-3 and magnesium co-supplemented with vitamin E in RCTs were 1000 mg/day and 250 mg/day, respectively. These trials reported the effects of vitamin E supplementation or vitamin E in combination with omega-3 or magnesium supplementation on anthropometric measurements, lipid and glycemic profiles, biomarkers of inflammation and oxidative stress, hormonal profile and hirsutism score.

Table 1.

The main characteristics of clinical trial studies which were included in the systematic review and meta-analysis.

Author, year Country Mean age/age range (year) (intervention/control) No. of participants (intervention/control) Study duration (wk) Control Intervention (content/dose) Outcome Intervention Control Adjustment or matching Quality score1
Before (mean ± SD) After (mean ± SD) Change (SD/SE/95% CI) Before (mean ± SD) After (mean ± SD) Change (SD/SE/95% CI)
Jamilian, 2018 Iran 18–40 (22.3 ± 4.7/24.4 ± 4.7 ) 40 (20/20) 12 Placebo (paraffin) 1000 mg omega-3 fatty acids plus 400 IU vitamin E supplements Anthropometric measurements Weight(kg) 73.6 ± 11.7 72.7 ± 11.8  − 0.9 ± 1.5 69.8 ± 17.1 69.4 ± 16.9  − 0.4 ± 1.1 Matched for age and BMI 6
BMI(kg/m2) 28.8 ± 5.1 28.5 ± 5.1  − 0.3 ± 0.6 26.5 ± 5.9 26.3 ± 5.8  − 0.2 ± 0.4
HC (cm) 102.1 ± 12.1 101.7 ± 13.1  − 0.4 ± 0.5 98.7 ± 12.6 98.6 ± 12.4  − 0.1 ± 1.0
WC (cm) 90.0 ± 12.7 89.6 ± 12.6  − 0.4 ± 0.5 87.1 ± 12.4 86.9 ± 12.2  − 0.2 ± 0.6
METs 27.9 ± 2.1 28.0 ± 2.2 0.1 ± 0.9 27.1 ± 1.9 27.2 ± 2.1 0.1 ± 0.6
Hirsutism mF-G 15.8 ± 4.0 15.1 ± 3.6  − 0.7 ± 0.9 14.1 ± 3.6 13.9 ± 3.3  − 0.2 ± 0.5
Rahmani, 2017 Iran 18–40 (24.9 ± 5.5/26.6 ± 5.6 ) 68 (34/34) 12 Placebo 1000 mg omega-3 fatty acids from flaxseed oil containing 400 mg α-linolenic acid plus 400 IU vitamin E supplements Anthropometric measurements Weight(kg) 74.1 ± 10.7 73.8 ± 10.8  − 0.3 ± 1.1 77.6 ± 18.2 77.4 ± 18.3  − 0.2 ± 1.1 Matched for age and phenotypes A and D of PCOS 7
BMI(kg/m2) 28.4 ± 4.4 28.2 ± 4.6  − 0.1 ± 0.4 29.0 ± 6.5 29.0 ± 6.5  − 0.1 ± 0.4
METs 29.4 ± 2.5 29.5 ± 2.5 0.1 ± 0.8 28.9 ± 2.3 28.8 ± 2.3  − 0.1 ± 0.8
Hormonal profile FSH (IU/L) 7.3 ± 2.5 7.2 ± 2.5  − 0.4 ± 0.5* 7.9 ± 2.8 8.1 ± 3.2 0.5 ± 0.5* Adjusted for baseline values, age and BMI at baseline
LH (IU/L) 11.0 ± 8.0 10.5 ± 8.9  − 1.2 ± 1.4* 13.5 ± 13.3 11.4 ± 7.7  − 1.5 ± 0.5*
oxidative stress TAC (mmol/L) 860.5 ± 101.0 949.9 ± 119.3 60.3 ± 19.1* 969.5 ± 85.3 975.4 ± 98.0 35 ± 19.2*
GSH (µmol/L) 525.3 ± 84.1 544.8 ± 81.3 21.7 ± 8.7* 511.8 ± 69.1 555.2 ± 62.4 41.1 ± 8.7*
MDA (µmol/L) 2.9 ± 0.6 2.5 ± 0.6  − 0.2 ± 0.1* 2.2 ± 0.5 2.2 ± 0.5  − 0.2 ± 0.1*
Biochemical profile TG (mg/dL) 122.7 ± 61.7 100.6 ± 54.0  − 21.9 ± 4* 120.6 ± 59.4 128.3 ± 72.6 7.5 ± 4*
VLDL-C (mg/dL) 24.5 ± 12.3 20.1 ± 10.8  − 4.4 ± 0.8* 24.1 ± 11.9 25.7 ± 14.5 1.5 ± 0.8*
TC(mg/dL) 181.8 ± 28.0 161.5 ± 31.4  − 18.1 ± 3.8* 166.4 ± 29.2 178.6 ± 29.9 10 ± 3.8*
LDL-c (mg/dL) 111.1 ± 26.5 94.4 ± 29.8  − 13.3 ± 3.7* 92.9 ± 25.5 104.8 ± 26.3 8.5 ± 3.7*
HDL-C (mg/dL) 46.2 ± 10.0 47.0 ± 9.5 0.2 ± 0.8* 49.4 ± 8.1 48.1 ± 9.3  − 0.7 ± 0.8*
TC/HDL-c 4.1 ± 1.0 3.6 ± 0.9  − 0.4 ± 0.1* 3.5 ± 0.8 3.9 ± 1.1 0.3 ± 0.1*
Ebrahimi, 2017 Iran 18–40 (23.8 ± 4.6/25.2 ± 5.2 ) 68 (34/34) 12 Placebo 1000 mg omega-3 fatty acids from flaxseed oil containing 400 mg α-Linolenic acid plus 400 IU vitamin E supplements Anthropometric measurements Weight (kg) 72.4 ± 10.7 71.9 ± 10.7 0  − 0.5 ± 1.3 75.1 ± 18.2 74.8 ± 18.3  − 0.3 ± 1.1 Matched for age, BMI and phenotypes A and D of PCOS 7
BMI(kg/m2) 28.0 ± 4.3 27.8 ± 4.3  − 0.2 ± 0.5 28.5 ± 6.6 28.3 ± 6.7  − 0.2 ± 0.4
METs 27.0 ± 2.3 27.0 ± 2.4 0.02 ± 0.7 26.8 ± 2.1 26.7 ± 2.2  − 0.1 ± 0.7
Biochemical profile FPG(mg/dL) 90.2 ± 10.2 87.0 ± 8.6  − 3.8 ± 1.1* 94.8 ± 7.4 94.1 ± 9.1  − 0.05 ± 1.1* Adjusted for baseline values, age and BMI at baseline
Insulin (μIU/mL) 10.8 ± 4.8 9.8 ± 4.9  − 0.8 ± 0.9* 9.8 ± 5.7 12.5 ± 6.6 2.5 ± 0.9*
HOMA-IR 2.4 ± 1.2 2.2 ± 1.2  − 0.2 ± 0.2* 2.3 ± 1.4 2.9 ± 1.6 0.6 ± 0.2*
HOMA-B 39.7 ± 18.6 35.4 ± 19.1  − 3.0 ± 3.3* 33.7 ± 21.4 44.1 ± 25.4 9.2 ± 3.3*
QUICKI 0.34 ± 0.02 0.34 ± 0.02 0.002 ± 0.005* 0.35 ± 0.04 0.33 ± 0.02  − 0.01 ± 0.005*
Hirsutism mF-G 13.6 ± 3.7 13.3 ± 3.7  − 0.4 ± 0.2* 12.2 ± 3.5 12.0 ± 3.4  − 0.3 ± 0.2*
Hormonal profile Total testosterone (ng/mL) 1.2 ± 0.9 0.7 ± 0.6  − 0.4 ± 0.08* 1.1 ± 0.6 1.0 ± 0.6  − 0.06 ± 0.08* 7
Free testosterone (pg/mL) 4.5 ± 3.2 3.3 ± 2.4  − 1.1 ± 0.3* 3.9 ± 2.7 3.7 ± 2.3  − 0.4 ± 0.3*
SHBG (nmol/L) 37.5 ± 15.9 44.1 ± 21.3 6.9 ± 2.4* 39.1 ± 15.0 44.9 ± 16.9 5.5 ± 2.4*
FAI 0.14 ± 0.13 0.09 ± 0.11  − 0.04 ± 0.01* 0.12 ± 0.17 0.08 ± 0.05  − 0.04 ± 0.01*
DHEAS 4.5 ± 2.3 3.5 ± 2.0  − 1.2 ± 0.2* 5.2 ± 1.9 4.3 ± 1.5  − 0.7 ± 0.2*
Izadi, 2019 Iran 20–40 (27.18 ± 5.77/ 26.0 ± 4.53) 43 (22/21) 8 Placebo 400 IU vitamin E Anthropometric measurements BMI(kg/m2) 29.28 ± 4.24 28.92 ± 4.23 ‒0.37 (‒0.60, ‒0.14)** 28.73 ± 3.39 28.74 ± 2.9 0.01 (‒0.23, 0.25)** – 7
WC (cm) 95.00 ± 10.82 92.18 ± 10.94 ‒2.81, (‒3.47, ‒2.15)** 89.33 ± 7.97 88.43 ± 8.04 ‒0.89, (‒1.57, ‒0.21)**
Biochemical profile TG (mg/dL) 111.68 ± 44.41 105.18 ± 8.22  − 6.48 (− 9.31, − 3.66)** 112.86 ± 42.27 112.09 ± 9.09  − 0.99 (− 3.89, 1.90)** Adjusted for baseline levels, age, physical activity, dietary intake of energy and vitamin E
TC (mg/dL) 163.41 ± 21.86 159.00 ± 18.96  − 4.07 (− 9.14, 1.00)** 157.43 ± 18.46 159.67 ± 22.87 2.37 (− 2.84, 7.57)**
LDL-C (mg/dL) 82.53 ± 20.51 78.10 ± 19.83  − 4.02 (− 9.60, 1.54)** 79.57 ± 24.17 82.53 ± 22.84 3.07 (− 2.64, 8.78)**
HDL-C (mg/dL) 58.54 ± 9.21 59.86 ± 8.45 1.24 (− 0.56, 3.05)** 55.28 ± 11.94 54.71 ± 9.81  − 0.5 (− 2.36, 1.35)**
Non-HDL-C (mg/dL) 104.86 ± 22.29 99.14 ± 19.78  − 5.32 (− 10.94, 0.31)** 102.14 ± 24.39 104.95 ± 24.79 2.87 (− 2.90, 8.64)**
Jamilian, 2019 Iran 18–40 (29.2 ± 7.2/28.3 ± 3.8 ) 60 (30/30) 12w Placebo 250 mg/day magnesium plus 400 mg/ day vitamin E supplements Anthropometrics measurements Weight(kg) 66.7 ± 9.5 66.6 ± 9.5 –0.1 ± 0.3 67.8 ± 10.9 67.7 ± 11.1 –0.1 ± 0.8 – 7
BMI(kg/m2) 25.5 ± 3.5 25.5 ± 3.3 –0.03 ± 0.1 26.0 ± 4.7 26.0 ± 4.7 –0.05 ± 0.3
Biochemical profile FPG(mg/dl) 92.1 ± 12.2 90.9 ± 11.9 –1.5 ± 1.0* 93.7 ± 5.8 94.4 ± 6.5 1.0 ± 1.0* Adjusted for baseline values + age and baseline BMI
TG (mg/dl) 125.0 ± 53.0 110.0 ± 55.0  − 15.1 ± 4.4* 128.1 ± 60.6 134.7 ± 68.9 6.8 ± 4.4*
VLDL-C (mg/dl) 25.0 ± 10.6 22.0 ± 11.0 –3.0 ± 9.9* 25.6 ± 12.1 26.9 ± 13.8 1.3 ± 0.9*
TC(mg/dl) 181.6 ± 40.4 174.5 ± 32.2 –7.2 ± 4.4* 185.0 ± 34.4 193.2 ± 33.7 8.3 ± 4.4*
LDL-C (mg/dl) 104.5 ± 36.0 101.4 ± 30.4 –2.7 ± 4.6* 106.2 ± 37.1 114.2 ± 38.9 7.6 ± 4.6*
HDL-C (mg/dl) 52.1 ± 10.1 51.1 ± 8.6 –1.1 ± 1.2* 53.1 ± 9.3 52.0 ± 10.9 –1.0 ± 1.2*
TC/HDL-C ratio – – –0.05 ± 0.1* – – 0.3 ± 0.1*
Insulin (μIU/mL) 13.4 ± 5.8 12.3 ± 5.0 –1.0 ± 0.5* 12.2 ± 5.1 13.9 ± 4.5 1.5 ± 0.5*
HOMA-IR 3.0 ± 1.4 2.8 ± 1.2  − 0.2 ± 0.1* 2.8 ± 1.2 3.2 ± 1.1 0.4 ± 0.1*
QUICKI 0.32 ± 0.01 0.33 ± 0.01 0.003 ± 0.003* 0.33 ± 0.02 0.32 ± 0.01  − 0.008 ± 0.003*
Izadi, 2019 Iran 20–40 (27.18 ± 5.77/ 26.0 ± 4.53) 43 (22/21) 8 Placebo 400 IU vitamin E Anthropometric measurements Weight (kg) 76.95 ± 10.61 75.96 ± 10.3  − 1.33 (− 0.4 to 2.29)** 73.23 ± 7.58 73.29 ± 7.3 0.15 (− 0.49 to 0.9)** – 7
Biochemical profile FBS(mg/dl) 85.50 ± 20.28 81.18 ± 10.28 4.32 (0.85 to 7.67)** 17.95 ± 9.25 80.57 ± 8.96  − 0.10 (− 3.69 to 3.48)** Adjusted for baseline values, age, BMI, and physical activity
Insulin (mIU/L) 13.72 ± 5.92 11.44 ± 4.57 2.26 (0.36 to 4.16)** 13.47 ± 9.73 12.47 ± 7.73 0.89 (1.14 to 2.78)**
HOMA-IR 2.80 ± 1.17 2.35 ± 1.01 0.45 (0.02 to 0.87)** 2.73 ± 2.12 2.55 ± 1.70 0.16 (− 0.28 to 0.60)**
Hormonal profile Total testosterone (ng/ml) 1.16 ± 0.40 0.84 ± 0.23 0.32 (0.17 to 0.46)** 1.33 ± 0.35 1.47 ± 0.39  − 0.13 (− 0.28 to 0.02)**
SHBG 38.00 (25.32 to 72.50)*** 54.10 (31.50 to 66.20)***  − 5.93 (− 16.08 to 4.23)** 42.30 (25.20 to 56.80)*** 40.80 (31.00 to 44.50)*** 1.05 (− 9.43 to 11.52)**
FAI 3.08 (1.57 to 8.13)*** 1.66 (1.14 to 2.92)*** 1.39 (0.47 to 2.32)** 2.80 (2.02 to 4.99)*** 3.53 (2.57 to 5.12)*** 0.42 (− 0.91 to 0.99)**
LH(mIU/ml) 11.15 (7.30 to 17.05)*** 7.25 (6.35 to 15.00)*** 4.88 (2.72 to 7.4)** 8.40 (5.200 to 17.85)*** 10.80 (6.70 to 17.95)***  − 0.49 (− 2.72 to 1.73)**
FSH (mIU/mL) 5.90 (5.27 to 6.77)*** 5.10 (3.75 to 6.27)*** 0.63 (− 0.46 to 1.72)** 7.30 (3.70 to 7.65)*** 5.90 (4.80 to 7.10)*** 0.21 (− 0.98 to 1.4)**
Progesterone (ng/mL) 1.80 ± 0.86 2.46 ± 1.02  − 0.0 (− 1.06 to − 0.27)** 1.62 ± 0.99 1.60 ± 1.12  − 0.02 (− 0.45 to 0.41)**
Estradiol (pg/mL) 85.45 ± 17.79 99.66 ± 23.01  − 13.92 (− 34.25 to 6.42)** 74.43 ± 17.95 71.09 ± 12.38 1.74 (− 20.36 to 23.85)**
Talari, 2018 Iran 18–40 60 (30/30) 12 Placebo 1000 mg omega-3 plus 400 IU vitamin E supplements Inflammatory markers hs-CRP (ng/mL) 2877.9 ± 2095.5 2487.3 ± 1673.1  − 360.2 ± 140.1 2646.7 ± 1492.3 2883.7 ± 1488.9 206.6 ± 140.1 Adjusted for baseline values, age, BMI at baseline 6
NO(μmol/L) 49.6 ± 2.3 51.3 ± 4.7 1.8 ± 0.7 46.0 ± 6.0 46.1 ± 5.9  − 0.05 ± 0.7
Shokrpour , 2019 Iran 18–40 (27.2 ± 7.1/26.0 ± 3.7) 60 (30/30) 12w Placebo 250 mg/day magnesium plus 400 mg/day vitamin E supplements Anthropometric measurements Weight (kg) 69.4 ± 10.7 69.2 ± 10.6  − 0.2 ± 0.3 70.9 ± 10.3 70.7 ± 10.4  − 0.1 ± 0.6 Matched for age and BMI 7
BMI(kg/m2) 27.1 ± 4.2 27.0 ± 4.1  − 0.1 ± 0.1 27.9 ± 4.2 27.8 ± 4.2  − 0.1 ± 0.2
Hirsutism mF-G 14.9 ± 2.9 14.6 ± 2.5 – 13.8 ± 3.8 13.8 ± 3.8 – –
Inflammatory markers hs-CRP (ng/mL) 3.7 ± 1.9 3.1 ± 1.7 – 3.5 ± 1.5 3.7 ± 1.5 –
NO(μmol/L) 34.4 ± 2.3 38.7 ± 4.0 – 36.6 ± 5.6 37.0 ± 5.8 –
Oxidative stress TAC (mmol/l) 522.4 ± 30.6 590.7 ± 52.2 – 513.7 ± 81.7 514.5 ± 77.3 –
GSH (μmol/L) 508.1 ± 69.1 519.4 ± 47.7 – 481.1 ± 101.2 483.8 ± 94.2 –
MDA (μmol/L) 2.7 ± 0.2 2.6 ± 0.2 – 2.4 ± 0.5 2.5 ± 0.5 –
Hormonal profile Total testosterone (ng/ml) 1.4 ± 0.8 1.3 ± 0.7 – 1.2 ± 0.5 1.2 ± 0.6 –
SHBG )nmol/l) 51.4 ± 26.4 62.9 ± 36.3 – 48.5 ± 15.1 49.2 ± 15.2 –
FAI 0.15 ± 0.16 0.11 ± 0.11 – 0.09 ± 0.05 0.09 ± 0.05 –
Sadeghi, 2019 Iran 18–40 (26.67 ± 3.35 /26.98 ± 3.78) 62 (32/30) 8w Placebo 2 g of omega-3 plus 400 IU of vitamin E Oxidative stress TAC(mg/dl) 12.42 ± 1.95 13.58 ± 2.06 1.15 ± 0.93 12.22 ± 1.91 12.16 ± 1.96  − 0.6 ± 0.72 – 6
Catalase (IU/L) 10.18 ± 1.27 12.01 ± 1.26 1.19 ± 1.06 11.14 ± 1.11 11.26 ± 1.15 0.12 ± 0.36
GLU (μmol/L) 10.65 ± 2.57 12.15 ± 2.66 1.5 ± 1.06 10.77 ± 2.53 11.00 ± 2.65 0.23 ± 1.43
MDA (μmol/L) 1.76 ± 0.29 1.42 ± 0.26  − 0.34 ± 0.32 1.38 ± 0.26 1.95 ± 2.23 0.57 ± 2.20
Shirazi, 2019 Iran 20–40 (27.18 ± 5.77 /26.0 ± 4.53) 43 (22/21) 8w Placebo 400 IU/day vitamin E -as alpha tocopheryl acetate Anthropometric measurements Weight (kg) 76.95 ± 10.61 75.96 ± 10.3 – 73.23 ± 7.58 73.29 ± 7.3 – Matched for age and BMI 7
BMI(kg/m2) 29.45 ± 5.35 29.07 ± 5.16 – 28.80 ± 3.71 28.83 ± 3.70 –
Open in a new tab

BMI body mass index, WC waist circumference, HC hip circumference, METs metabolic equivalents, FBS fasting blood sugar, FPG fasting plasma glucose, HOMA-β the homeostasis model assessment-β cell function, HOMA-IR the homeostasis model, QUICKI quantitative insulin sensitivity check index, TG triglyceride, HDL-c high density lipoprotein cholesterol, LDL-c low density lipoprotein cholesterol, VLDL-c very low-density lipoprotein-cholesterol, TC TCesterol, TAC total antioxidant capacity, NO nitric oxide, hs-CRP high sensitive C-reactive protein, MDA malondialdehyde, GSH glutathione, LH serum luteinizing hormone, FSH follicle stimulating hormone, FAI free androgen index, SHBG sex hormone-binding globulin, DHEAS dehydroepiandrosterone sulfate, GLU glutathione, mF-G ferriman–Gallwey.

1According to Cochrane quality score.

*SE.

** 95% CI.

***IQR.

In case of sample size of the included RCTs, considering a type one error (α) of 5% and power of 80 or 90%, along with HOMA-IR, TG, hs-CRP and progesterone as the key outcome variables, sample size for each intervention group was calculated by the use of the proposed formula for parallel clinical trials. In almost all studies, an acceptable sample size was included in the final analysis2,14–18,20,22,23.

Quality of included studies

Details of quality assessment of included articles are presented in Supplemental Table S2. All eligible RCTs have adequately performed random sequence generation; however, one RCT (10%) was judged as having some concern for allocation concealment20. All RCTs have adequately done blinding of participants and personnel and blinding of outcome assessment. One RCT (10%) was judged as high risk of bias for incomplete outcome data21, and one RCT (10%) was judged as high risk of bias for selective outcome reporting22. All RCTs showed a low risk for other sources of bias. Overall, seven RCTs (70%) were rated as low risk of bias2,14–18,23, and two others (20%) were rated as having high certainty of bias21,22, due to incomplete outcome data and selective outcome reporting and the last RCT (10%) was rated as some concern20.

Meta-analysis of the effects of vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation on lipid profile

The effect of supplementation on lipid profile in PCOS patients was examined in 3 RCTs17,18,23 (with 171 subjects). Overall, we found a significant reduction in serum levels of TG (weighted mean difference (WMD): − 18.27 mg/dL, 95% CI − 34.68 to − 1.87), VLDL (WMD: − 5.88 mg/dL, 95% CI − 8.08 to − 3.68), LDL-c (WMD: − 12.84 mg/dL, 95% CI − 22.15 to − 3.52), TC (WMD: − 16.30 mg/dL, 95% CI − 29.74 to − 2.86) and TC /HDL-c ratio (WMD: − 0.52, 95% CI − 0.87 to − 0.18) after vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation in comparison to placebo, while the observed increase in HDL-c level was not statistically significant (Fig. 2). There was a significant heterogeneity between studies in the case of TG (I2 = 90.1%, P < 0.001) and TC (I2 = 82.1%, P = 0.004). To find the source of heterogeneity, meta-regression was conducted based on age and duration of intervention. Between-study heterogeneity was removed after these meta-regressions for age (for TG: β = − 0.008, P = 0.98, I2 residual = 0.00%; for TC: β = 0.028, P = 0.94, I2 residual = 0.00%) and duration of intervention (for TG: β = − 0.187, P = 0.55, I2 residual = 0.00%; for TC: β = − 0.194, P = 0.63, I2 residual = 0.00%), although the regression coefficients were not statistically significant. Subgroup analysis could not be performed, due to the small number of eligible trials.

Figure 2.

Figure 2

Open in a new tab

Forest plots of the effect of vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation on lipid profile. If the diamond does not touch the vertical line (or the line of null effect), the overall effect is statistically significant. Significant reductions were found in serum levels of TG (WMD: − 18.27 mg/dL, 95% CI − 34.68 to − 1.87), VLDL (WMD: − 5.88 mg/dL, 95% CI − 8.08 to − 3.68), LDL-c (WMD: − 12.84 mg/dL, 95% CI − 22.15 to − 3.52), TC (WMD: − 16.30 mg/dL, 95% CI − 29.74 to − 2.86) and TC /HDL-c ratio (WMD: − 0.52, 95% CI − 0.87 to − 0.18) in PCOS patients after vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation in comparison to placebo.

Meta-analysis of the effects of vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation on biomarkers of inflammation and oxidative stress

A total of 3 RCTs14,21,23 with 190 participants were included in this analysis. Meta-analysis could not show any beneficial effect for vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation on TAC (WMD: 31.69 mmol/L, 95% CI − 20.89 to 84.27), GSH (WMD: − 4.53 µmol/L, 95% CI − 31.91 to 22.86) and MDA (WMD: − 0.20 µmol/L, 95% CI − 0.46 to 0.07). However, a slight but significant decrease in hs-CRP (WMD: − 0.60 ng/mL, 95% CI − 0.77 to − 0.44) and a significant increase in NO levels (WMD: 2.79 µmol/L, 95% CI 0.79–4.79) were found (Fig. 3). There was a significant heterogeneity among trials in case of TAC (I2 = 96.8%, P < 0.001) and NO (I2 = 90.3%, P = 0.001). For TAC, meta-regression based on age (β = − 0.003, P = 0.98, I2 residual = 0.00%) and duration of intervention (β = 0.062, P = 0.71, I2 residual = 0.00%) removed the observed heterogeneity, although regression coefficients for these covariates were not significant.

Figure 3.

Figure 3

Open in a new tab

Forest plots of the effect of vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation on biomarkers of inflammation and oxidative stress. If the diamond does not touch the vertical line (or the line of null effect), the overall effect is statistically significant. A significant decrease in serum level of hs-CRP (WMD − 0.60 ng/mL, 95% CI − 0.77 to − 0.44) and a significant increase in the serum level of NO (WMD: 2.79 µmol/L, 95% CI 0.79–4.79) were found in PCOS patients after vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation in comparison to placebo.

Meta-analysis of the effects of vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation on glycemic indices

As shown in Fig. 4, pooling effect sizes from 3 RCTs15–17 with 171 subjects showed a non-significant reduction in FBS (WMD = − 1.08 mg/dL, 95% CI − 5.07 to 2.91), insulin (WMD = − 1.47 µIU/mL, 95% CI − 4.15 to 1.22), HOMA-IR (WMD = − 0.40, 95% CI − 0.95 to 0.15) and no change in QUICKI (WMD = 0.01, 95% CI 0.00–0.02) in PCOS patients after vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation, as compared to placebo. A significant heterogeneity was found among the studies in case of FBS (I2 = 75.1%, P = 0.018), insulin (I2 = 82.5%, P = 0.003) and HOMA-IR (I2 = 75.9%, P = 0.016). Meta-regression was performed to find the probable effect of age and duration of the intervention (as covariates) on heterogeneity. Findings showed that age (for FBS: β = 0.079, P = 0.91, I2 residual = 74.89%; for insulin: β = 0.101, P = 0.92, I2 residual = 89.14; for HOMA-IR: β = 0.601, P = 0.90, I2 residual = 99.49%) could not significantly explain the observed heterogeneity, but duration of intervention (for FBS: β = − 0.510, P = 0.39, I2 residual = 0.00%; for insulin: β = − 0.959, P = 0.19, I2 residual = 0.00%; for HOMA-IR: β = − 3.944, P = 0.12, I2 residual = 85.81) could resolve the observed heterogeneity for FBS and insulin.

Figure 4.

Figure 4

Open in a new tab

Forest plots of the effect of vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation on glycemic indexes. If the diamond does not touch the vertical line (or the line of null effect), the overall effect is statistically significant. No significant effects of vitamin E supplementation or vitamin E supplementation plus omega-3 or magnesium on glycemic indices were found in PCOS patients.

Meta-analysis of the effects of vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation on hormonal profile

Effect sizes of 3 eligible RCTs14–16 (with 171 subjects) were pooled; no significant effect for vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation was found [total testosterone (WMD = 0.00 mg/mL, 95% CI − 0.42 to 0.43), LH (WMD = 2.79 mIU/mL, 95% CI − 2.18 to 7.76), FSH (WMD = − 0.30 mIU/mL, 95% CI − 1.59 to 0.99), SHBG (WMD = 3.26 nmol/L, 95% CI − 5.71 to 12.24) and FAI (WMD = − 0.02, 95% CI − 0.06 to 0.03)] (Fig. 5). Between-study heterogeneity was significant in case of total testosterone (I2 = 93.2%, P < 0.001), LH (I2 = 81.1%, P = 0.021), SHBG (I2 = 70.5%, P = 0.034) and FAI (I2 = 66.9%, P = 0.049). Meta-regression based on age (for total testosterone: β = 2.195, P = 0.48, I2 residual = 99.36%; for SHBG: β = 0.094, P = 0.85, I2 residual = 0.00%; for FAI: β = 0.986, P = 0.71, I2 residual = 99.98%) and duration of intervention (for total testosterone: β = − 5.448, P = 0.19, I2 residual = 99.08; for FAI: β = − 3.923, P = 0.11, I2 residual = 95.63%) could not resolve the observed heterogeneity for total testosterone and FAI, while this analysis removed the observed heterogeneity for SHBG (β = 0.129, P = 0.79, I2 residual = 0.00%).

Figure 5.

Figure 5

Open in a new tab

Forest plots of the effect of vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation on hormonal profile. If the diamond does not touch the vertical line (or the line of null effect), the overall effect is statistically significant. No significant effect of vitamin E supplementation or vitamin E plus omega-3 or magnesium supplementation on hormonal profile was found in PCOS patients.

Meta-analysis of the effects of vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation on anthropometric indices and hirsutism

As illustrated in Supplemental Fig. S1, vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation had no effect on weight (WMD = − 0.12 kg, 95% CI − 0.28 to 0.05), BMI (WMD = − 0.01 kg/m2, 95% CI − 0.07 to 0.05) and waist circumference (WMD = − 1.00 cm, 95% CI − 2.69 to 0.68) in PCOS patients. However, a significant decrease in hirsutism score (WMD = − 0.33, 95% CI − 0.65 to − 0.02) was observed among PCOS patients, after vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation as compared to placebo (Supplemental Fig. S2). There was no significant heterogeneity between studies in the case of hirsutism score and anthropometric measurements except for waist circumference (I2 = 91.3%, P = 0.001). Due to the small number of RCTs, subgroup analysis or meta-regression could not be performed for waist circumference.

Sensitivity analysis and publication bias

Sensitivity analysis indicated that overall effect sizes for body weight and BMI variables did not substantially change after the elimination of each included study. Sensitivity analysis was not performed for other outcomes, due to the small number of eligible studies. Publication bias was not assessed, since the limited number of effect sizes (< 10 per each outcome) rendered the interpretation of the statistical tests unreliable25.

Discussion

The current meta-analysis on 10 RCTs with 504 women with PCOS showed that vitamin E supplementation or vitamin E in combination with omega-3 or magnesium could result in significant decreases in lipid profile (TG, TC, LDL-c, VLDL, TC/HDL-c), hs-CRP and hirsutism score and an increase in NO concentration. Vitamin E supplementation or vitamin E, along with omega-3 or magnesium co-supplementation, had no impact on glycemic indices, hormonal profile, other biomarkers of inflammation or oxidative stress, anthropometric measurements, and HDL-c levels. So, the positive effect of vitamin E in PCOS might be independent of weight loss. Our findings highlighted the potential anti-hyperlipidemic, anti-oxidant, and anti-inflammatory properties of vitamin E on PCOS; therefore, this vitamin could be used as an adjunctive therapy for the management of some clinical manifestations and complications of PCOS.

Similar to our findings, a recent meta-analysis on RCTs showed that omega-3 and vitamin E co-supplementation could have beneficial effects on lipid profiles among overweight patients with metabolic syndrome26. In another meta-analysis on nine RCTs, omega-3 fatty acid supplementation among PCOS patients could decrease circulating TC, and TG concentrations10. Contrary to our findings, a meta-analysis on RCTs showed that vitamin E plus omega-3 fatty acid co-supplementation could reduce VLDL levels, but did not change other lipid indices among subjects with a wide range of metabolic disorders27. Also, in a meta-analysis of fifteen RCTs, it was shown that supplementation with tocotrienols did not reduce the concentrations of LDL-c, TC and TG of participants with various clinical conditions, while an increase in HDL-c levels was observed28. It is also worth noting that in most previous investigations, the term vitamin E was often synonymously used with α-tocopherol, while α-tocopherol is only one of eight natural forms of vitamin E, and new findings have suggested various properties for different forms of vitamin E29. In addition, among the investigations included in the present meta-analysis, only one study has specified the form of vitamin E as alpha-tocopheryl acetate2. In contrast, other articles did not specify the type of vitamin E supplemented with.

In line with our findings, a recent meta-analysis investigated the effects of vitamin E and omega-3 fatty acids co-supplementation on oxidative stress and inflammation among patients with different diseases and reported a significant decrease in hs-CRP and an increase in NO. Also, no significant effect on MDA or GSH was detected30. Similar to our findings, another meta-analysis on eight RCTs showed that vitamin E supplementation had no effect on BMI or insulin resistance (HOMA-IR) among patients with NAFLD; this investigation on NAFLD patients has also shown that vitamin E did not significantly change TG and TC levels, but decreased LDL-c concentrations31. Another meta-analysis on fourteen RCTs has documented no effect for vitamin E supplementation on glycemic profile (HbA1c, FBS, and fasting insulin) in patients with T2DM32. Although among all these mentioned investigations, the outcomes of interest (including metabolic syndrome, NAFLD, T2DM, and PCOS) were related to insulin resistance, these prior meta-analyses had different study populations, inclusion and exclusion criteria for eligible studies, type and dose of supplementation (vitamin E or omega 3 or vitamin E plus omega 3 co-supplementation), and gender of the study population. So, different methodology aspects led to different findings. More trials are needed to shed light on the effect of vitamin E supplementation on PCOS and other metabolic disorders.

NO is a signaling molecule with a large number of functions in the immune system, the nervous system and apoptosis. NO has additionally a key role in the pathogenesis of inflammation. It has an anti-inflammatory effect under normal physiological situations; whereas, it is considered as a pro-inflammatory mediator that induces inflammation due to overproduction in abnormal conditions33. This overproduction of NO as an inflammatory mediator can lead to tissue destruction such as in inflammatory autoimmune diseases. Therefore, NO is a ‘double-edged sword’ mediator; depending on the concentration, it has pro- or anti-inflammatory effects33,34. On the other hand, various established non-steroidal anti-inflammatory medications with NO releasing properties have been under intense clinical evaluations in the treatment of inflammatory disorders35. In case of women with PCOS, a previous meta-analysis on 12 case–control studies has documented that serum or plasma nitrite levels in patients with this syndrome were lower than healthy controls36. The current meta-analysis added the point that vitamin E supplementation alone and in combination with omega-3 or magnesium could significantly increase plasma NO levels in PCOS patients compared to controls. Therefore, this increment in NO concentration can be considered as an anti-inflammatory effect for NO in PCOS patients, although further investigations are required to understand the whole picture of such mediator.

Several mechanisms were suggested for the possible effects of vitamin E supplementation on various metabolic parameters. Chronic exposure to oxidative stress can impair lipid metabolism. Therefore, one hypothesis is that vitamin E improves lipid metabolism by reducing oxidative stress18. Anti-inflammatory and antioxidative effects of vitamin E may be explained by suppressing nuclear factor-kappa B (NF-κB) and JAK-signal transducer and activator of transcription 6 (STAT6) or JAK-STAT3 signaling pathways37. Moreover, tocotrienols can also downregulate the peroxisome proliferator-activated receptor gamma (PPARγ)38, which is a crucial mediator of adipogenesis39. Tocotrienols also possess dazzling lipid-lowering effects, such as downregulating 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA) reductase and hence suppressing cholesterol synthesis38; hypocholesterolemic properties of tocotrienols are extended to inhibition of cholesterol absorption in the intestines, as well40.

There are several possible mechanisms underlying the association between vitamin E and glucose metabolism. Vitamin E, a fat-soluble antioxidant, can suppress reactive oxygen species (ROS) generation in the pancreas and maintain the structural integrity of pancreatic islets in experimental diabetes41. Furthermore, there are some evidence that vitamin E supplementation could inhibit the glycation of hemoglobin32,41 and partially reverse the beta-cell apoptosis caused by oxidative stress41,42.

The present systematic review and meta-analysis was the first one, to our knowledge, that assessed the effect of vitamin E supplementation or vitamin E in combination with omega-3 or magnesium on women with PCOS. We performed a methodologically strict systematic review of the literature. No evidence of substantial heterogeneity in this meta-analysis was found. However, our study has several limitations. The number of included RCTs was small, so we could not perform stratified analysis based on vitamin E vs. vitamin E plus omega 3 or magnesium supplementation. The included RCTs applied small sample sizes with relatively short intervention periods. Also, most of the eligible articles did not specify the type of vitamin E supplemented with. Finally, dietary intakes of vitamin E, omega-3 and magnesium were not considered in most included trials.

In conclusion, this study demonstrated that vitamin E supplementation or vitamin E in combination with omega-3 or magnesium co-supplementation might have beneficial effects on serum concentrations of TG, TC, LDL-c, VLDL, TC/HDL-c, hs-CRP, NO, and hirsutism score in PCOS patients. No significant effect was found in the case of glycemic indices, hormonal profile, anthropometric measurements, HDL-c levels, and other biomarkers of inflammation or oxidative stress. Additional well-designed clinical trials are needed to affirm these findings.

Supplementary Information

Supplementary Information. (84.2KB, docx)

Abbreviations

PCOS

Polycystic ovary syndrome

T2DM

Type 2 diabetes mellitus

CVD

Cardiovascular diseases

WMD

Weighted mean differences

95% CI

95% Confidence intervals

RCT

Randomized clinical trial

PRISMA

Preferred reporting items for systematic reviews and meta-analyses guideline

FBS

Fasting blood sugar

HDL-c

High-density lipoprotein-cholesterol

LDL-c

Low-density lipoprotein-cholesterol

TG

Triglycerides

TC

Total cholesterol

VLDL

Very low-density lipoprotein-cholesterol

MDA

Malondialdehyde

TAC

Total antioxidant capacity

GSH

Glutathione

hs-CRP

High sensitive C-reactive protein

NO

Nitric oxide

CRP

C-reactive protein

IL-6

Interleukin-6

TNF-α

Tumor necrosis factor-α

LH

Serum luteinizing hormone

FSH

Follicle stimulating hormone;

HOMA-IR

Homeostasis model assessment-estimated insulin resistance

QUICKI

Quantitative insulin sensitivity check index

SHB

Sex hormone-binding globulin

FAI

Free androgen index

BMI

Body mass index

WC

Waist circumference

METs

Metabolic equivalents

mf-G

Modified Ferriman–Gallwey

mg

Milligram

kg

Kilogram

μmol

Micro-mol

dL

Deciliter

IU

International unit

Author contributions

H.H., Z.H., and P.S. contributed to conception, design, statistical analyses, data interpretation and manuscript drafting. All authors approved the final manuscript for submission.

Funding

The financial support for this study comes from the Nutrition and Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran (no. 240095). Nutrition and Food Security Research Center had no role in the design/conduct of the study, collection/analysis/interpretation of the data, and preparation/review/approval of the manuscript. The financial support for conception, design, data analysis and manuscript drafting come from Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Data availability

The datasets used and analyzed during the current study are available from the corresponding author (Dr. Parvane Saneei at email: saneeip@yahoo.com) upon reasonable request.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-022-24467-0.

References

  • 1.Sadeghi A, Djafarian K, Mohammadi H, Shab-Bidar S. Effect of omega-3 fatty acids supplementation on insulin resistance in women with polycystic ovary syndrome: Meta-analysis of randomized controlled trials. Diabetes Metab Syndr. 2017;11(2):157–162. doi: 10.1016/j.dsx.2016.06.025. [DOI] [PubMed] [Google Scholar]
  • 2.Shirazi S, Gargari BP, Izadi A, Taghizadeh S, Parizad M. Effect of vitamin E on serum levels of vascular endothelial growth factor and angiopoietin-1 in women with polycystic ovary syndrome: A pilot randomized, placebo-controlled trial. Int. J. Fert. Steril. 2021;15(1):44. doi: 10.22074/IJFS.2020.45677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Setji TL, Brown AJ. Polycystic ovary syndrome: update on diagnosis and treatment. Am. J. Med. 2014;127(10):912–919. doi: 10.1016/j.amjmed.2014.04.017. [DOI] [PubMed] [Google Scholar]
  • 4.Mohammadi S, Kayedpoor P, Karimzadeh-Bardei L, Nabiuni M. The effect of curcumin on TNF-α, IL-6 and CRP expression in a model of polycystic ovary syndrome as an inflammation state. J. Reprod. Infert. 2017;18(4):352. [PMC free article] [PubMed] [Google Scholar]
  • 5.Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH, et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: A case-control study. J. Clin. Endocrinol. Metab. 2008;93(2):470–476. doi: 10.1210/jc.2007-1756. [DOI] [PubMed] [Google Scholar]
  • 6.Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J. Clin. Endocrinol. Metab. 2010;95(5):2038–2049. doi: 10.1210/jc.2009-2724. [DOI] [PubMed] [Google Scholar]
  • 7.Tal, R., Seifer, D. B., Arici, A., editors. The emerging role of angiogenic factor dysregulation in the pathogenesis of polycystic ovarian syndrome. Seminars in reproductive medicine. Thieme Medical Publishers (2015). [DOI] [PubMed]
  • 8.Abramovich D, Irusta G, Bas D, Cataldi NI, Parborell F, Tesone M. Angiopoietins/TIE2 system and VEGF are involved in ovarian function in a DHEA rat model of polycystic ovary syndrome. Endocrinology. 2012;153(7):3446–3456. doi: 10.1210/en.2012-1105. [DOI] [PubMed] [Google Scholar]
  • 9.Heydarpour F, Hemati N, Hadi A, Moradi S, Mohammadi E, Farzaei MH. Effects of cinnamon on controlling metabolic parameters of polycystic ovary syndrome: A systematic review and meta-analysis. J. Ethnopharmacol. 2020;254:112741. doi: 10.1016/j.jep.2020.112741. [DOI] [PubMed] [Google Scholar]
  • 10.Yang K, Zeng L, Bao T, Ge J. Effectiveness of Omega-3 fatty acid for polycystic ovary syndrome: A systematic review and meta-analysis. Reprod. Biol. Endocrinol. 2018;16(1):27. doi: 10.1186/s12958-018-0346-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil. Steril. 2002;77(6):1095–1105. doi: 10.1016/S0015-0282(02)03111-4. [DOI] [PubMed] [Google Scholar]
  • 12.Mehrabian F, Khani B, Kelishadi R, Ghanbari E. The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria. Endokrynol. Pol. 2011;62(3):238–242. [PubMed] [Google Scholar]
  • 13.Wong SK, Chin K-Y, Suhaimi FH, Ahmad F, Ima-Nirwana S. Vitamin E as a potential interventional treatment for metabolic syndrome: evidence from animal and human studies. Front. Pharmacol. 2017;8:444. doi: 10.3389/fphar.2017.00444. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Shokrpour M, Asemi Z. The effects of magnesium and vitamin E co-supplementation on hormonal status and biomarkers of inflammation and oxidative stress in women with polycystic ovary syndrome. Biol. Trace Elem. Res. 2019;191(1):54–60. doi: 10.1007/s12011-018-1602-9. [DOI] [PubMed] [Google Scholar]
  • 15.Ebrahimi FA, Samimi M, Foroozanfard F, Jamilian M, Akbari H, Rahmani E, et al. The effects of omega-3 fatty acids and vitamin E co-supplementation on indices of insulin resistance and hormonal parameters in patients with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial. Exp. Clin. Endocrinol. Diabetes. 2017;125(06):353–359. doi: 10.1055/s-0042-117773. [DOI] [PubMed] [Google Scholar]
  • 16.Izadi A, Ebrahimi S, Shirazi S, Taghizadeh S, Parizad M, Farzadi L, et al. Hormonal and metabolic effects of coenzyme Q10 and/or vitamin E in patients with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2019;104(2):319–327. doi: 10.1210/jc.2018-01221. [DOI] [PubMed] [Google Scholar]
  • 17.Jamilian M, Sabzevar NK, Asemi Z. The effect of magnesium and vitamin E co-supplementation on glycemic control and markers of cardio-metabolic risk in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Horm. Metab. Res. 2019;51(02):100–105. doi: 10.1055/a-0749-6431. [DOI] [PubMed] [Google Scholar]
  • 18.Izadi A, Shirazi S, Taghizadeh S, Gargari BP. Independent and additive effects of coenzyme Q10 and vitamin E on cardiometabolic outcomes and visceral adiposity in women with polycystic ovary syndrome. Arch. Med. Res. 2019;50(2):1–10. doi: 10.1016/j.arcmed.2019.04.004. [DOI] [PubMed] [Google Scholar]
  • 19.Chen J, Guo Q, Pei Y-H, Ren Q-L, Chi L, Hu R-K, et al. Effect of a short-term vitamin E supplementation on oxidative stress in infertile PCOS women under ovulation induction: A retrospective cohort study. BMC Womens Health. 2020;20:1–9. doi: 10.1186/s12905-020-00930-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Talari HR, Poladchang S, Hamidian Y, Samimi M, Gilasi HR, Ebrahimi FA, et al. The effects of omega-3 and vitamin E co-supplementation on carotid intima-media thickness and inflammatory factors in patients with polycystic ovary syndrome. Oman Med. J. 2018;33(6):473. doi: 10.5001/omj.2018.88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Sadeghi F, Alavi-Naeini A, Mardanian F, Ghazvini MR, Mahaki B. Omega-3 and vitamin E co-supplementation can improve antioxidant markers in obese/overweight women with polycystic ovary syndrome. Int. J. Vit. Nutr. Res. 2019;1:1. doi: 10.1024/0300-9831/a000588. [DOI] [PubMed] [Google Scholar]
  • 22.Jamilian M, Shojaei A, Samimi M, Ebrahimi FA, Aghadavod E, Karamali M, et al. The effects of omega-3 and vitamin E co-supplementation on parameters of mental health and gene expression related to insulin and inflammation in subjects with polycystic ovary syndrome. J. Affect. Disord. 2018;229:41–47. doi: 10.1016/j.jad.2017.12.049. [DOI] [PubMed] [Google Scholar]
  • 23.Rahmani E, Samimi M, Ebrahimi FA, Foroozanfard F, Ahmadi S, Rahimi M, et al. The effects of omega-3 fatty acids and vitamin E co-supplementation on gene expression of lipoprotein (a) and oxidized low-density lipoprotein, lipid profiles and biomarkers of oxidative stress in patients with polycystic ovary syndrome. Mol. Cell. Endocrinol. 2017;439:247–255. doi: 10.1016/j.mce.2016.09.008. [DOI] [PubMed] [Google Scholar]
  • 24.Eldridge, S., Campbell, M., Campbell, M., Drahota-Towns, A., Giraudeau, B., Higgins, J., et al. Revised Cochrane risk of bias tool for randomized trials (RoB 2.0): additional considerations for cluster-randomized trials (2016).
  • 25.Higgins, J. P., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J. et al. Cochrane handbook for systematic reviews of interventions: John Wiley & Sons (2019). [DOI] [PMC free article] [PubMed]
  • 26.Asbaghi O, Choghakhori R, Abbasnezhad A. Effect of Omega-3 and vitamin E co-supplementation on serum lipids concentrations in overweight patients with metabolic disorders: A systematic review and meta-analysis of randomized controlled trials. Diabetes Metab. Syndr. 2019;13(4):2525–2531. doi: 10.1016/j.dsx.2019.07.001. [DOI] [PubMed] [Google Scholar]
  • 27.Sepidarkish M, Morvaridzadeh M, Akbari-Fakhrabadi M, Almasi-Hashiani A, Rezaeinejad M, Heshmati J. Effect of omega-3 fatty acid plus vitamin E Co-Supplementation on lipid profile: A systematic review and meta-analysis. Diabetes Metab. Syndr. 2019;13(2):1649–1656. doi: 10.1016/j.dsx.2019.03.018. [DOI] [PubMed] [Google Scholar]
  • 28.Zuo S, Wang G, Han Q, Xiao H, et al. The effects of tocotrienol supplementation on lipid profile: A meta-analysis of randomized controlled trials. Complement Ther. Med. 2020;52:102450. doi: 10.1016/j.ctim.2020.102450. [DOI] [PubMed] [Google Scholar]
  • 29.Sen CK, Khanna S, Roy S. Tocotrienols: Vitamin E beyond tocopherols. Life Sci. 2006;78(18):2088–2098. doi: 10.1016/j.lfs.2005.12.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Moosavian SP, Arab A, Mehrabani S, Moradi S, Nasirian M. The effect of omega-3 and vitamin E on oxidative stress and inflammation: Systematic review and meta-analysis of randomized controlled trials. Int. J. Vitam. Nutr. Res. 2020;90(5–6):553–563. doi: 10.1024/0300-9831/a000599. [DOI] [PubMed] [Google Scholar]
  • 31.Vadarlis A, Antza C, Bakaloudi DR, Doundoulakis I, Kalopitas G, Samara M, et al. Systematic review with meta-analysis: The effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2021;36(2):311–319. doi: 10.1111/jgh.15221. [DOI] [PubMed] [Google Scholar]
  • 32.Xu R, Zhang S, Tao A, Chen G, Zhang M. Influence of vitamin E supplementation on glycaemic control: A meta-analysis of randomised controlled trials. PLoS ONE. 2014;9(4):e95008. doi: 10.1371/journal.pone.0095008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Sharma JN, Al-Omran A, Parvathy SS. Role of nitric oxide in inflammatory diseases. Inflammopharmacology. 2007;15(6):252–259. doi: 10.1007/s10787-007-0013-x. [DOI] [PubMed] [Google Scholar]
  • 34.Bredt DS, Snyder SH. Nitric oxide: A physiologic messenger molecule. Annu. Rev. Biochem. 1994;63:175–195. doi: 10.1146/annurev.bi.63.070194.001135. [DOI] [PubMed] [Google Scholar]
  • 35.Marshall M, Keeble J, Moore PK. Effect of a nitric oxide releasing derivative of paracetamol in a rat model of endotoxaemia. Br. J. Pharmacol. 2006;149(5):516–522. doi: 10.1038/sj.bjp.0706855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Meng C. Nitric oxide (NO) levels in patients with polycystic ovary syndrome (PCOS): A meta-analysis. J. Int. Med. Res. 2019;47(9):4083–4094. doi: 10.1177/0300060519864493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Jiang Q. Natural forms of vitamin E: Metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy. Free Radical. Biol. Med. 2014;72:76–90. doi: 10.1016/j.freeradbiomed.2014.03.035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Pang K-L, Chin K-Y. The role of tocotrienol in protecting against metabolic diseases. Molecules. 2019;24(5):923. doi: 10.3390/molecules24050923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Wang Y-X. PPARs: Diverse regulators in energy metabolism and metabolic diseases. Cell. Res. 2010;20(2):124–137. doi: 10.1038/cr.2010.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Bardhan J, Chakraborty R, Raychaudhuri U. The 21st century form of vitamin E-Tocotrienol. Curr. Pharm. Des. 2011;17(21):2196–2205. doi: 10.2174/138161211796957472. [DOI] [PubMed] [Google Scholar]
  • 41.Pazdro R, Burgess JR. The role of vitamin E and oxidative stress in diabetes complications. Mech. Ageing Dev. 2010;131(4):276–286. doi: 10.1016/j.mad.2010.03.005. [DOI] [PubMed] [Google Scholar]
  • 42.Jin L, Xue H-Y, Jin L-J, Li S-Y, Xu Y-P. Antioxidant and pancreas-protective effect of aucubin on rats with streptozotocin-induced diabetes. Eur. J. Pharmacol. 2008;582(1–3):162–167. doi: 10.1016/j.ejphar.2007.12.011. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information. (84.2KB, docx)

Data Availability Statement

The datasets used and analyzed during the current study are available from the corresponding author (Dr. Parvane Saneei at email: saneeip@yahoo.com) upon reasonable request.

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES